COQ3 is the most significant survival-altering gene in EAC, which also could be potentially susceptible to the complex I inhibitor metformin (Cameron et al., 2018), which has already been shown to be beneficial in esophageal cancer with combination therapy (Qie et al., 2019). Here, COQ3 is linked to esophageal cancer.